Oncolys BioPharma Inc.
4588.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.08 | 0.26 | 0.16 |
| FCF Yield | -17.89% | -13.30% | -18.82% | -19.52% |
| EV / EBITDA | -5.65 | -4.73 | -7.06 | -3.89 |
| Quality | ||||
| ROIC | -54.63% | -107.54% | -47.16% | -35.53% |
| Gross Margin | 100.00% | 48.55% | 34.67% | 30.94% |
| Cash Conversion Ratio | 1.20 | 0.69 | 1.50 | 1.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -68.20% | -53.88% | 45.92% | -21.01% |
| Free Cash Flow Growth | -50.72% | 21.87% | 1.42% | -18.76% |
| Safety | ||||
| Net Debt / EBITDA | 1.10 | 0.50 | 0.94 | 1.69 |
| Interest Coverage | -365.76 | -535.81 | -305.32 | -348.90 |
| Efficiency | ||||
| Inventory Turnover | 0.18 | 6.07 | 26.30 | 38.07 |
| Cash Conversion Cycle | 3,241.39 | -1,526.76 | 98.10 | 122.24 |